CFOR — CapForce Share News
0.000.00%
Last trade - 00:00- $24.36m
- $23.83m
- $30.20m
Brief: Opgen Reports Q2 Loss Per Share $0.13
OpGen Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: OpGen Subsidiary Ares Genetics GmbH Enters Into Collaboration Agreement With Belgian National Reference Centre For Invasive S. Pneumoniae At UZ Leuven
U.S. RESEARCH ROUNDUP- Chipotle Mexican Grill, Domino's Pizza, McDonald's
Brief: OpGen Announces Preliminary Unaudited Revenue And Cash Position For Second Quarter 2022
Brief: Opgen Inc Says Entered Into An At-The-Market Common Stock Sales Agreement For Up To $10.7 Million Of Common Stock - SEC Filing
Brief: OpGen Announces Publication Of Results Of Unyvero Hospitalized Pneumonia Panel
Brief: OpGen Says 1,000th Patient Sample Enrolled In Clinical Trial For Unyvero UTI Panel
Brief: Opgen Subsidiary Curetis And Leader Life Sciences Enter Into Unyvero Distribution Partnership For U.A.E., Qatar
Brief: OpGen Reports Q1 2022 Financial Results
OpGen Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Curetis, European Investment Bank Plan to Restructure Debt Repayment
U.S. STOCKS ON THE MOVE-OpGen Inc, Anthem Inc, Dow Inc
OpGen gains as unit launches new genome sequencing services
Brief: OpGen Subsidiary Ares Genetics Commercially Launches New Sequencing And Analysis Services Globally
Brief: Opgen's Subsidiary Ares Genetics Provides Update On Collaboration Agreement To Drive Cutting-Edge Digital Solutions In Global Fight Against Antimicrobial Resistance
U.S. STOCKS ON THE MOVE-PVH, Aterian, First Solar
U.S. STOCKS ON THE MOVE-System1, Domino's Pizza, Sunshine Biopharma
OpGen to continue UTI panel study as planned, shares up